- Home
- HCC vs ARWR Comparison
HCC vs ARWR Comparison
Compare HCC & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- ARWR
- Stock Information
- Founded
- HCC 2015
- ARWR 2003
- Country
- HCC United States
- ARWR United States
- Employees
- HCC N/A
- ARWR N/A
- Industry
- HCC Coal Mining
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- HCC Energy
- ARWR Health Care
- Exchange
- HCC Nasdaq
- ARWR Nasdaq
- Market Cap
- HCC 2.8B
- ARWR 2.6B
- IPO Year
- HCC 2017
- ARWR 1993
- Fundamental
- Price
- HCC $46.22
- ARWR $19.90
- Analyst Decision
- HCC Strong Buy
- ARWR Buy
- Analyst Count
- HCC 5
- ARWR 11
- Target Price
- HCC $75.00
- ARWR $43.33
- AVG Volume (30 Days)
- HCC 755.0K
- ARWR 2.5M
- Earning Date
- HCC 02-13-2025
- ARWR 02-10-2025
- Dividend Yield
- HCC 0.69%
- ARWR N/A
- EPS Growth
- HCC N/A
- ARWR N/A
- EPS
- HCC 4.79
- ARWR N/A
- Revenue
- HCC $1,525,220,000.00
- ARWR $2,500,000.00
- Revenue This Year
- HCC $4.64
- ARWR $3,336.78
- Revenue Next Year
- HCC $11.97
- ARWR $124.29
- P/E Ratio
- HCC $9.65
- ARWR N/A
- Revenue Growth
- HCC N/A
- ARWR N/A
- 52 Week Low
- HCC $45.94
- ARWR $17.05
- 52 Week High
- HCC $75.53
- ARWR $36.72
- Technical
- Relative Strength Index (RSI)
- HCC 30.42
- ARWR 49.40
- Support Level
- HCC $52.27
- ARWR $17.57
- Resistance Level
- HCC $50.81
- ARWR $21.84
- Average True Range (ATR)
- HCC 2.19
- ARWR 1.06
- MACD
- HCC -0.48
- ARWR 0.11
- Stochastic Oscillator
- HCC 2.99
- ARWR 54.57
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.